{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:59:51Z","timestamp":1775584791404,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ejca.2011.09.023","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T15:45:00Z","timestamp":1320162300000},"page":"1476-1483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel\/carboplatin chemotherapy: Cell type is the most useful prognostic factor"],"prefix":"10.1016","volume":"48","author":[{"given":"A.","family":"Bamias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sotiropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Trachana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kostouros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kakoyianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Haidopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Thomakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Antsaklis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.09.023_b0005","first-page":"1151","article-title":"Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","article-title":"Early events in the pathogenesis of epithelial ovarian cancer","volume":"26","author":"Landen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma. Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e3181788546","article-title":"A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary","volume":"33","author":"Kobel","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian cancer","volume":"39","author":"Gilks","year":"2008","journal-title":"Human Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0030","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.24915","article-title":"Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy","volume":"116","author":"Bamias","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.09.023_b0035","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdq257","article-title":"Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience","volume":"21","author":"Alexandre","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.25460","article-title":"Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study","volume":"117","author":"Zaino","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.09.023_b0045","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as a prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis analysis of 3 prospectively randomized phase III trials","volume":"115","author":"Du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.09.023_b0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2011.09.023_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2009.09.029","article-title":"Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications","volume":"116","author":"Kobel","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathological grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silveberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2559.2007.02912.x","article-title":"Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems","volume":"52","author":"Singh","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2011.09.023_b0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00428-009-0725-y","article-title":"Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study","volume":"454","author":"Kommoss","year":"2009","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ejca.2011.09.023_b0075","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2005.12.038","article-title":"Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience","volume":"102","author":"Pectasides","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0085","series-title":"World Health Organization classification of tumours: pathology and genetics. Tumours of the breast and female genital organs","year":"2003"},{"key":"10.1016\/j.ejca.2011.09.023_b0090","first-page":"1","article-title":"Classification and staging of malignant tumors in the female pelvis","volume":"50","author":"International Federation of Gynecology and Obstetrics","year":"1971","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejca.2011.09.023_b0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading of ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0100","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/PAS.0b013e31816fd555","article-title":"Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data","volume":"32","author":"Vang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0110","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2011.09.023_b0130","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2011.09.023_b0135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004347-200210000-00011","article-title":"Histopathologic features of genetically determined ovarian cancer","volume":"21","author":"Shaw","year":"2002","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0140","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2011.06.033","article-title":"Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin\/paclitaxel chemotherapy: A single institution experience","volume":"123","author":"Bamias","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2011.09.023_b0150","first-page":"7052","article-title":"Loss of heterozygosity on 10pq23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence from benign endometrial cyst to endometrioid carcinomas and clear-cell carcinoma of the ovary","volume":"60","author":"Sato","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.09.023_b0155","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1054\/bjoc.2001.1950","article-title":"Analysis of TGF-beta functional pathway in epithelial ovarian carcinoma","volume":"85","author":"Francis-Thickpenny","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.09.023_b0160","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejca.2011.09.023_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0b013e3181af2372","article-title":"Prognostic factors for stage I ovarian carcinoma","volume":"29","author":"Seidman","year":"2010","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0170","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/PAS.0b013e3181a24354","article-title":"Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis","volume":"33","author":"Ayhan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0175","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading of ovarian serous carcinomas","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2011.09.023_b0180","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e3181e1a3bb","article-title":"Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study","volume":"34","author":"K\u00f6bel","year":"2010","journal-title":"Am J Surg Pathol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911007362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911007362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:03:59Z","timestamp":1775581439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911007362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0959804911007362"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.09.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel\/carboplatin chemotherapy: Cell type is the most useful prognostic factor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2011.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}